THE MAIN GOAL OF OUR COMPANY IS TO INCREASE THE LIFE EXPECTANCY AND TO IMPROVE QUALITY OF LIFE.
We have created an innovative biopharmaceuticals company that is focused on long-term development. In collaboration with our partners, and by applying cutting-edge science and management, we are able to solve our patients' serious health problems.
Our key objective is to adopt creative and professional approaches to our tasks. We are always mindful of the fact that big achievements are the outcome of patience and hard work.
Acquisition and accumulation of new knowledge is the foundation of our business. This allows us to discover new ways of addressing our patients’ health problems and to improve their conditions so that they can lead a happy life.
Building a socially-oriented business that is based on the principles of respect for human rights and creating a positive environment around you is one of the primary goals at our company. Using all opportunities, we contribute to the economic development of our society, recognizing that this is important to long-term health of our business.
WE ARE A FULL CYCLE RUSSIAN BIOPHARMACEUTICAL COMPANY, HOLDING THE LEADING POSITION FOR INVESTMENT ATTRACTIVENESS AMONG LEADING PHARMACEUTICAL COMPANIES.
We pay the utmost attention to our patients. Patient satisfaction and quality of life are our paramount guiding principles in the development and manufacturing of drugs. Therefore, we consider it important to identify directly the needs of patients and to be proactive by creating drugs that can treat diseases that are currently non-curable.
Our products are more valuable to patients than their price.
We are open to cooperation with significant synergy potential and a view to robust expansion of our markets based on mutual benefits Understanding the complexity of the challenges we face, we stay within our core competencies, and we use all opportunities from our related knowledge. We do this by strengthening our own research and development activities, and by actively working with our colleagues - scientists, doctors and pharmacists.
We believe that our capital is in our personnel. Realizing that the results of our operations are long-term, we create effective teams that are built on the principles of trust, understanding, support, teamwork, self-improvement, and generational continuity and that are focused on better results.
Our policy with respect to employees is built on the principles of maximum use of capacity and potential of each and every employee . We reward those who exceed expectations and have outstanding results. We attract highly skilled employees, and for this we have created a corporate culture and social climate that encourages skilled and ambitious people.
We build our relationships with our stakeholders based on openness, trust and mutual understanding, and strive to increase the value of their investments. We believe that increased confidence in the company is the primary factor in the increase of capitalization.
We are socially responsible and active company. We honor and abide by the laws of countries where we do business. We clearly understand our position in society and defend it if necessary.
Extensive clinical research is being conducted. Clinical studies of rituximab have been approved in:
The company produces original biological products as well as generic biotech drugs.
Every employee of BIOCAD has unique experience and knowledge.
We are confident that our projects and comfortable work environment will allow you to fully express your individuality, apply your talents and abilities, gain invaluable experience and become an integral part of the team. Working at BIOCAD gives you an outstanding chance to contribute to your own success and professional growth.
NUMBER OF RESEARCHERS
Currently more than 130 employees of BIOCAD are involved in the creation and study of new drugs, and 20 of employees have advanced science degrees.
We are the leader among Russian manufacturers measured by number of clinical trials.
21 clinical trial by August 2012
19 permits for clinical trials in the first nine months of 2012
Deputy CEO for Manufacturing and Technical Support, Executive Director of BIOCAD
Alexander Grachev was born on November 25, 1979 in Moscow.
He graduated from the Bauman Moscow State Technical University, and in 2006—from the I.M. Sechenov Moscow Medical Academy (MMA).
Alexander Grachev joined BIOCAD in 2002. He became Chief of the Manufacturing Department in 2006 and was promoted to Deputy CEO for Manufacturing and Technical Support in 2009.
In 2012, he was appointed Executive Director.
Deputy CEO for Legal and Administrative Affairs
Alexey Katkov was born on September 23, 1980 in Odintsovsky District of Moscow Oblast.
He graduated from the Moscow State Social University with a degree in jurisprudence.
He began his career in Lactis, LLC in 2000, and then held a number of positions in Group of Companies “NIKA”.
In 2006, he became Chief of the Legal Department at BIOCAD.
He has been a member of the Board of Directors of BIOCAD since August 2012.
Alexey Katkov has been holding the position of Deputy CEO for Legal and Administrative Affairs and been in charge of the Moscow Branch of BIOCAD since September 2012.
In September 2014, he was appointed CEO of Biocad-Pharm, LLC, a BIOCAD subsidiary.
Alexey provides the legal support for all business activities of Group of Companies BIOCAD, supervises the intellectual property protection of BIOCAD, and is in charge of the manufacturing facilities in the Moscow region.
Deputy CEO for Human Resources
Alexandra Glazkova was born on June 27, 1987.
Alexandra has graduated in 2009 from the Faculty of Statistics, Accounting and Economic Analysis from the Saint Petersburg State University of Economics and Finance. Thereafter, Alexandra received her Master Degree in International Business Administration (Hamburg, Germany).
Alexandra has started her career in Red Bull marketing department; she has also acted as a MINI car sales manager in BMW dealer. Since 2009, Alexandra continued her professional career as a personal assistant for chief executives at Consulting Holding “Platonov and Partners” and Johnson Controls Automotive.
Since 2011, Alexandra Glazkova is working at a biopharmaceutical company “BIOCAD”. For over two years, she was serving as a personal assistant to the owner/CEO of the company. Under Alexandra’s supervision an impressive amount of corporate projects have been realized - full rebranding of the company, HR brand development, as well as successfully establishing the following systems: recruitment, motivation, training and development program, talent pool program, etc.
Since the beginning of 2014, Alexandra has took up the position of CEO Deputy for Human Resources Management.
Deputy CEO for Sales and Marketing
Deputy CEO for Economics and Finance, BIOCAD
Alexander Gushchin was born in 1983 in Saint Petersburg.
In 2006, he graduated from the Faculty of Statistics, Accounting, and Economic Analysis at the Saint Petersburg State University of Economics and Finance.
From 2005 to 2014, he worked as an auditor in the audit and consulting company PwC.
Alexander Gushchin has been holding the position of Deputy CEO for Economics and Finance in BIOCAD since 2014.
Deputy CEO for Biomedical Studies and Development
Roman Ivanov was born in 1977 in Yekaterinburg.
In 2000, he graduated from the Faculty of General Medicine at the Ural State Medical Academy (USMA).
In 2005, he obtained a PhD in molecular immunology in the Utrecht University (Netherlands).
Roman Ivanov worked in the Department of Hematology, University Medical Center Utrecht, and developed methods of immunogene therapy of hematological malignancies.
In 2005-2010, he held the position of Medical Director in the biopharmaceutical company BIOCAD.
Since 2011, he has been serving as Vice President for Research and Development in the biopharmaceutical company BIOCAD.
Dmitry Morozov was born in 1965 in Moscow.
He graduated from the Faculty of Radio Engineering at the State Academy of Consumer Goods and Services (Moscow).
In 1997-1998, he attended the course of Banking and Finance at the Plekhanov Russian Academy of Economics (Moscow) and earned the qualification of economist.
In 1998, he successfully completed the program “Master of Business Administration” in the Moscow International Higher Business School MIRBIS and received the Master of Management degree.
Under the Presidential Program, he was training in the Keio Business School of the Keio University in 2004.
Dmitry Morozov is a member of the Council for the Development of Pharmaceutical and Medical Industry of the Russian Government.
He is among the individuals (top 500) included into the High-Potential Management Personnel Reserve under the auspices of the Russian President.
Dmitry Morozov is also a member of the Work Team of the Scientific and Coordinating Council for the Federal Targeted Program “Research and Development in Priority Areas of Development of the Russian Scientific and Technological Complex for 2007-2012” for the priority area “Living Systems”.
He co-authored the concept of Pharma 2020 - Governmental program for development of Russian pharmaceutical industry .
Until late 1990’s, he held the position of Deputy Chairman of the Board in CentroCredit Bank.
Dmitry Morozov founded BIOCAD in 2001.